Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents
详细信息 查看全文
- 作者：Junya Kuroda (1)
Yuji Shimura (1)
Kensuke Ohta (2)
Hirokazu Tanaka (3)
Hirohiko Shibayama (4)
Satoru Kosugi (5)
Shinichi Fuchida (6)
Masayuki Kobayashi (7)
Hitomi Kaneko (8)
Nobuhiko Uoshima (9)
Kazuyoshi Ishii (10)
Shosaku Nomura (10)
Masafumi Taniwaki (1)
Akifumi Takaori-Kondo (7)
Chihiro Shimazaki (6)
Mitsuru Tsudo (8)
Masayuki Hino (11)
Itaru Matsumura (3)
Yuzuru Kanakura (4) - 关键词：Multiple myeloma ; Melphalan ; Prednisolone ; Novel agent ; International staging system
- 刊名：International Journal of Hematology
- 出版年：2014
- 出版时间：April 2014
- 年：2014
- 卷：99
- 期：4
- 页码：441-449
- 全文大小：499 KB
- 参考文献：1. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV. San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 2013;121:884-2. CrossRef
2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-0. CrossRef
3. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281-0. CrossRef
4. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013;27:2351-. CrossRef
5. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22:3269-6. CrossRef
6. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055-6. CrossRef
7. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30:1953-. CrossRef
8. Kuroda J, Nagoshi H, Shimura Y, Taniwaki M. Elotuzumab and Daratumumab: emerging new monoclonal antibodies for multiple myeloma. Expert Rev Anticancer Ther. 2013;28:368-3.
9. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. Blood. 1968;31:1-0.
10. Bergsagel DE, Sprague CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. l -Phenylalanine mustard (NSC-8806). Cancer Chemother Rep. 1962;21:87-9.
11. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209-8. CrossRef
12. Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 2009;113:3435-2. CrossRef
13. Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Bj?rkstrand B, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116:1405-2. CrossRef
14. Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28:3160-. CrossRef
15. Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118:1231-. CrossRef
16. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-1. CrossRef
17. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-7. CrossRef
18. Hernández JM, García-Sanz R, Golvano E, Bladé J, Fernandez-Calvo J, Trujillo J, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol. 2004;127:159-4. CrossRef
19. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28:2259-6. CrossRef
20. Medical Research Council’s Working Party on Leukaemia in. Adults. Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council’s Working Party on Leukaemia in Adults. Br J Cancer. 1980;42:823-0. CrossRef
21. Myeloma Trialists-Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists-Collaborative Group. J Clin Oncol. 1998;16:3832-2.
22. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-0. CrossRef
23. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-3. CrossRef
24. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksa? M, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118:1239-7. CrossRef
25. Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011;25:689-6. CrossRef
26. Watanabe R, Tokuhira M, Kizaki M. Current approaches for the treatment of multiple myeloma. Int J Hematol. 2013;97:333-4. CrossRef
27. Tan D, Kim K, Kim JS, Eom HS, Teoh G, Ong KH, et al. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Leuk Res. 2013;37:1070-. CrossRef
28. Maltezas D, Dimopoulos MA, Katodritou I, Repousis P, Pouli A, Terpos E, et al. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. Hematol Oncol. 2013;31:356-2. CrossRef
29. Kleber M, Ihorst G, Gross B, Koch B, Reinhardt H, W?sch R, et al. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk. 2013;13:541-1. CrossRef
30. Zhuang J, Da Y, Li H, Han B, Wan X, Zhu T, et al. Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. Leuk Res. 2014;38:188-3.
31. Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol. 2011;94:310-0. CrossRef
32. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025-1. CrossRef
33. Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115:4168-3. CrossRef
34. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia. 2009;23:1941-6. CrossRef
35. Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, et al. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol. 2013;162:348-9. CrossRef
36. Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J. 2013;3:e148. CrossRef
37. Caldarella C, Isgrò MA, Treglia I, Treglia G. Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma? Int J Hematol. 2012;96:685-1. CrossRef
38. Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, et al. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. Int J Hematol. 2012;95:516-6. CrossRef
39. Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, W?sch R, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J. 2011;1:e35. CrossRef
40. Bataille R, Annweiler C, Beauchet O. Multiple myeloma international staging system: “staging-or simply “aging-system? Clin Lymphoma Myeloma Leuk. 2013;13:635-. CrossRef - 作者单位：Junya Kuroda (1)
Yuji Shimura (1)
Kensuke Ohta (2)
Hirokazu Tanaka (3)
Hirohiko Shibayama (4)
Satoru Kosugi (5)
Shinichi Fuchida (6)
Masayuki Kobayashi (7)
Hitomi Kaneko (8)
Nobuhiko Uoshima (9)
Kazuyoshi Ishii (10)
Shosaku Nomura (10)
Masafumi Taniwaki (1)
Akifumi Takaori-Kondo (7)
Chihiro Shimazaki (6)
Mitsuru Tsudo (8)
Masayuki Hino (11)
Itaru Matsumura (3)
Yuzuru Kanakura (4)
1. Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan
2. Department of Hematology, Osaka Saiseikai Nakatsu Hospital, 2-10-39 Shibata, Kita-ku, Osaka, 530-0012, Japan
3. Department of Hematology and Rheumatology, Kinki University Faculty of Medicine, Sayama, Osaka, 589-8511, Japan
4. Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan
5. Department of Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Osaka, 560-8565, Japan
6. Department of Hematology, Social Insurance Kyoto Hospital, Kyoto, 603-8151, Japan
7. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
8. Department of Hematology, Osaka Red Cross Hospital, Osaka, 543-8555, Japan
9. Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Osaka, 570-8540, Japan
10. First Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka, 570-0074, Japan
11. Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan - ISSN：1865-3774
文摘
We retrospectively investigated clinical outcomes and prognostic factors of 131 patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) who received melphalan and prednisolone (MP) as first-line therapy from 2006 to 2013. Eighty-one patients received salvage therapies incorporating bortezomib, lenalidomide, and/or thalidomide. The overall response rate to MP was 54.2?%, including 9.2?% of better than very good partial response. With a median follow-up period of 30.2?months, median overall survival (OS) and median time to next treatment (TNT) were 54.4 and 19.0?months, respectively. Univariate analysis revealed that performance status and serum calcium level significantly associated with both OS and TNT, and multivariate analysis revealed that the higher serum calcium level had a significantly unfavorable impact on OS and TNT. Importantly, staging informed by the international staging system (ISS) was not predictive for OS or TNT in the analyzed cohort. Our study revealed that, in the context of first-line MP therapy for NDMM, the salvage therapy incorporating novel agents produced a survival period of >30?months after the initiation of second-line therapy, suggesting that the predictive value of ISS for OS and TNT may be limited in the era of novel agents.